242 related articles for article (PubMed ID: 31707429)
1. Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients.
Choudhury S; Agrawal A; Pantvaidya G; Shah S; Purandare N; Puranik A; Rangarajan V
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):547-553. PubMed ID: 31707429
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
[TBL] [Abstract][Full Text] [Related]
3. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
4. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
5. Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation.
Park JH; Moon GS; Nam KT; Yoon JH
Ann Surg Oncol; 2021 Oct; 28(11):6580-6589. PubMed ID: 33677764
[TBL] [Abstract][Full Text] [Related]
6. Referral Practice for Radioactive Iodine Ablation (RAI) after ATA guidelines 2015: results from a Tertiary Cancer Care Centre.
Dhar H; Thiagarajan S; Yousuf A; Nayyar SS; Chaukar D
Eur Arch Otorhinolaryngol; 2020 Sep; 277(9):2521-2526. PubMed ID: 32240364
[TBL] [Abstract][Full Text] [Related]
7. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
8. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
[No Abstract] [Full Text] [Related]
10. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation.
Hong CM; Lee WK; Jeong SY; Lee SW; Ahn BC; Lee J
Nucl Med Commun; 2014 Nov; 35(11):1119-26. PubMed ID: 25144561
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318
[TBL] [Abstract][Full Text] [Related]
12. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
13. Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma.
Moore MD; Postma E; Gray KD; Ullmann TM; Hurley JR; Goldsmith S; Sobel VR; Schulman A; Scognamiglio T; Christos PJ; Hassett E; Luick J; Whitehall D; Zarnegar R; Fahey TJ
World J Surg; 2018 Feb; 42(2):343-349. PubMed ID: 29058064
[TBL] [Abstract][Full Text] [Related]
14. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.
Castagna MG; Maino F; Cipri C; Belardini V; Theodoropoulou A; Cevenini G; Pacini F
Eur J Endocrinol; 2011 Sep; 165(3):441-6. PubMed ID: 21750043
[TBL] [Abstract][Full Text] [Related]
15. Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal.
Monos S; Fritz C; Harris J; Romeo D; Ng JJ; Xu K; Cooperberg B; Moreira A; Rajasekaran K
Otolaryngol Head Neck Surg; 2024 Jan; 170(1):20-33. PubMed ID: 37694597
[TBL] [Abstract][Full Text] [Related]
16. Radioactive iodine therapy.
Lee SL
Curr Opin Endocrinol Diabetes Obes; 2012 Oct; 19(5):420-8. PubMed ID: 22914564
[TBL] [Abstract][Full Text] [Related]
17. Shifting paradigms in the management of pediatric differentiated thyroid cancer from static to dynamic risk stratification: a step forward toward precision medicine.
Ajdari SE; Shafiei B; Motazedian M; Qutbi M; Esmaeilzadeh P; Asli IN; Javadi H; Assadi M
Nuklearmedizin; 2019 Jun; 58(3):249-257. PubMed ID: 31060081
[TBL] [Abstract][Full Text] [Related]
18. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
20. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]